Viridian Therapeutics Inc. (0K1R:LSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Viridian Therapeutics Inc. stock forecast from 0 analysts, the average analyst target price for Viridian Therapeutics Inc. is not available over the next 12 months. Viridian Therapeutics Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Viridian Therapeutics Inc. is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Viridian Therapeutics Inc.’s stock price was USD 15.46. Viridian Therapeutics Inc.’s stock price has changed by -5.33% over the past week, -11.96% over the past month and -47.24% over the last year.
No recent analyst target price found for Viridian Therapeutics Inc.
No recent average analyst rating found for Viridian Therapeutics Inc.
Company Overview Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Read Less
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the ...Read More
Frequently Asked Questions About Viridian Therapeutics Inc. (0K1R:LSE) Stock
Stock Target Advisor's fundamental analysis for Viridian Therapeutics Inc.'s stock is Very Bearish.
Unfortunately we do not have enough data on 0K1R:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0K1R:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 0K1R:LSE's stock to indicate if its overvalued.
The last closing price of 0K1R:LSE's stock was USD 15.46.
The most recent market capitalization for 0K1R:LSE is USD 39.62B.
Unfortunately we do not have enough analyst data on 0K1R:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Viridian Therapeutics Inc.'s stock.
As per our most recent records Viridian Therapeutics Inc. has 94 Employees.
Viridian Therapeutics Inc.'s registered address is 221 Crescent Street, Waltham, MA, United States, 02453.
You can get more information about it from Viridian Therapeutics Inc.'s website at https://www.viridiantherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0K1R:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
